Evaluation of liver fibrosis: Concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection

Clinical Infectious Diseases

Volumn 52, Issue 9, 2011, Pages 1164-1173

  Mendeni, Monia ^a   Foc, Emanuele ^a   Gotti, Daria ^a   Ladisa, Nicoletta ^c   Angarano, Gioacchino ^c   Albini, Laura ^a   Castelnuovo, Filippo ^b   Carosi, Giampiero ^a   Quiros Roldan, Eugenia ^a   Torti, Carlo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NUCLEOSIDE ANALOG; VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INTRAVENOUS DRUG ABUSE; KAPLAN MEIER METHOD; KAPPA STATISTICS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; VIRUS LOAD;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79953865880     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir071     Document Type: Article

References (34)

1. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
2. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-41. (Pubitemid 44232373)
3. Sulkowski MS, Metha SH, Montes de Occa R, Moore RD, Thomas DL. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C [abstract 842]. In: Programs and abstracts 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, 2006.
4. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10:116.
5. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-7. (Pubitemid 351920629)
6. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25. (Pubitemid 43980111)
7. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26. (Pubitemid 36919874)
8. Sulkowski MS, Metha SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-92. (Pubitemid 40543981)
9. Cozzi Lepri A, Prosperi M, Lo Caputo S, et al. Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona foundation study. Italian Conference on AIDS and Retroviruses Brescia, Italy. 20-22 June 2010. Infection 2010; 38(Suppl 1):73.
10. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performances of noninvasive markers of fibrosis for the diagnosis of hepatic C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40:538-44. (Pubitemid 41669157)
11. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6:375-8. (Pubitemid 41723304)
12. Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking is associated with an elevated aspartate aminotranferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med 2009; 10:133-42.
13. Blackard J, Welge J, Taylor L, et al. HIV mono-infection is associated with a non-invasive index of liver fibrosis in women. Clin Infect Dis 2011; 52:674-90.
14. Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005; 5:58.
15. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-6. (Pubitemid 47171918)
16. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32(Suppl 1):52-7.
17. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912-21. (Pubitemid 47436137)
18. Tural C, Tor J, Sanvisens A, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009; 7:339-45.
19. Tahan V, Canbakan B, Balci H, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008; 55:1433-8.
20. Niemelä O. Biochemical markers in alcoholism. Clin Chim Acta 2007; 377:39-49.
21. Cohen JA. Coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20:37-46.
22. Cohen JA. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70:213-20.
23. Cicchetti DV, Allison T. A New procedure for assessing reliability of scoring EEG sleep recordings. Am J EEG Technol 1971; 11:101-9.
24. Zeremski M, Talal AH. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 2006; 43:373-6. (Pubitemid 44078911)
25. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-82. (Pubitemid 43884712)
26. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested casecontrol study. Clin Infect Dis 2009; 49:626-35.
27. ACTG, AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases, Division of AIDS, 1992.
28. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24:1171-6.
29. Setzer B, Schlesier M, Walker U. Effects of didanosine-related depletion of mtDNA in human T lymphocytes. J Infect Dis 2005; 191:848-55. (Pubitemid 40349798)
30. Lee H, Hanes J, Johnson K. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42:14711-19. (Pubitemid 37553499)
31. Roge BT, Katzenstein TL, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing aba-cavir, didanosine and stavudine. Antivir Ther 2003; 8:173-82. (Pubitemid 36565898)
32. Buffet M, Schwarzinger M, Amellal B, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lip-oatrophy. J Clin Virol 2005; 33:60-4. (Pubitemid 40431578)
33. Chamie G, Bonacini M, Bangsberg DR, et al. Factor Associated with seronegative chronic hepatitis C virus Infection in HIV Infection. Clin Infect Dis 2007; 44:577-83. (Pubitemid 46233263)
34. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis in patients with chronic hepatitis C. Lancet 1997; 349:825.